Nautilus Biotechnology, Inc. announced its financial results for the third quarter ended September 30, 2024. The company reported a GAAP EPS of -$0.13 for the quarter.
This reported EPS figure surpassed analysts' consensus estimates by $0.04, indicating a stronger financial performance than anticipated by the market.
The company continues to focus on the development of its single-molecule proteome analysis platform, with ongoing progress in its core technology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.